National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità, Viale Regina Elena, 299 Rome, Italy.
Vaccine. 2012 Jan 5;30(2):109-11. doi: 10.1016/j.vaccine.2011.11.013. Epub 2011 Nov 17.
The objective of this study, conducted within the I-MOVE project, was to estimate pandemic VE against laboratory confirmed cases in two Italian regions using the screening method. We calculated vaccine coverage using the number of first doses of pandemic vaccine administered and demographic data. A case was defined as a patient who was swabbed from week 44 of 2009 to week 3 of 2010 and who tested positive for A/H1N1v using RT-PCR. A case was considered vaccinated against influenza A/H1N1v if she/he had received one dose of the vaccine more than 14 days before swabbing. We used Farrington's method to build the confidence intervals. We included in the analysis 755 confirmed A/H1N1v cases. The median age of cases was 24 years (range 0-89). One case (0.1%) had received one dose of vaccine more than 14 days after swabbing. The overall crude estimated VE was 92.4% (95% CI: 46.3-98.9). It suggests that the pandemic vaccine offered good protection against medically attended laboratory-confirmed A/H1N1v.
本研究旨在通过筛查法估计意大利两个地区针对实验室确诊病例的大流行疫苗有效性。我们使用接种的大流行疫苗第一针数量和人口统计数据计算疫苗覆盖率。病例定义为在 2009 年第 44 周至 2010 年第 3 周期间接受拭子检测且 RT-PCR 检测 A/H1N1v 呈阳性的患者。如果患者在接受拭子检测前 14 天以上接种过一剂疫苗，则认为其对 A/H1N1v 具有流感疫苗保护作用。我们使用 Farrington 方法构建置信区间。我们共纳入 755 例确诊的 A/H1N1v 病例。病例的中位年龄为 24 岁（范围 0-89）。1 例（0.1%）患者在接受拭子检测后 14 天以上接种过一剂疫苗。总体估计粗 VE 为 92.4%（95%CI：46.3-98.9）。这表明大流行疫苗对有医疗护理的实验室确诊 A/H1N1v 提供了良好的保护。
